<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/69329">
      <dc:title>Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress</dc:title>
      <dc:creator>Melguizo Alonso, Consolación</dc:creator>
      <dc:creator>Ortiz Quesada, Raúl</dc:creator>
      <dc:creator>Quiñonero Muñoz, Francisco José</dc:creator>
      <dc:creator>García Pinel, Beatriz</dc:creator>
      <dc:creator>Fuel, Marco</dc:creator>
      <dc:creator>Mesas Hernández, Cristina</dc:creator>
      <dc:creator>Cabeza Montilla, Laura</dc:creator>
      <dc:creator>Prados Salazar, José Carlos</dc:creator>
      <dc:subject>Drug resistance</dc:subject>
      <dc:subject>Colon cancer</dc:subject>
      <dc:subject>Pancreatic cancer</dc:subject>
      <dc:subject>Nanomedicine</dc:subject>
      <dc:subject>Cancer stem cells</dc:subject>
      <dc:subject>PARP</dc:subject>
      <dc:subject>miRNAs</dc:subject>
      <dc:subject>Tumor Microenvironment</dc:subject>
      <dc:description>The development of drug resistance is one of the main causes of cancer treatment failure.&#xd;
This phenomenon occurs very frequently in different types of cancer, including colon and pancreatic&#xd;
cancers. However, the underlying molecular mechanisms are not fully understood. In recent years,&#xd;
nanomedicine has improved the delivery and efficacy of drugs, and has decreased their side effects.&#xd;
In addition, it has allowed to design drugs capable of avoiding certain resistance mechanisms of&#xd;
tumors. In this article, we review the main resistance mechanisms in colon and pancreatic cancers,&#xd;
along with the most relevant strategies offered by nanodrugs to overcome this obstacle. These&#xd;
strategies include the inhibition of efflux pumps, the use of specific targets, the development of&#xd;
nanomedicines affecting the environment of cancer-specific tissues, the modulation of DNA repair&#xd;
mechanisms or RNA (miRNA), and specific approaches to damage cancer stem cells, among others.&#xd;
This review aims to illustrate how advanced nanoformulations, including polymeric conjugates,&#xd;
micelles, dendrimers, liposomes, metallic and carbon-based nanoparticles, are allowing to overcome&#xd;
one of the main limitations in the treatment of colon and pancreatic cancers. The future development&#xd;
of nanomedicine opens new horizons for cancer treatment.</dc:description>
      <dc:date>2021-06-22T08:43:11Z</dc:date>
      <dc:date>2021-06-22T08:43:11Z</dc:date>
      <dc:date>2021</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Ortíz, R.; Quiñonero, F.; García-Pinel, B.; Fuel, M.; Mesas, C.; Cabeza, L.; Melguizo, C.; Prados, J. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Cancers 2021, 13, 2058. https://doi.org/ 10.3390/cancers13092058</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/69329</dc:identifier>
      <dc:identifier>10.3390/cancers13092058</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>